Dicerna Pharmaceuticals Inc (DRNA) Forecasted to Post Q1 2019 Earnings of ($0.43) Per Share

Dicerna Pharmaceuticals Inc (NASDAQ:DRNA) – Investment analysts at SunTrust Banks issued their Q1 2019 earnings per share (EPS) estimates for Dicerna Pharmaceuticals in a research note issued on Tuesday, March 12th. SunTrust Banks analyst E. Nash expects that the biopharmaceutical company will post earnings of ($0.43) per share for the quarter. SunTrust Banks has a “Buy” rating and a $26.00 price target on the stock. SunTrust Banks also issued estimates for Dicerna Pharmaceuticals’ Q2 2019 earnings at ($0.25) EPS, Q3 2019 earnings at ($0.27) EPS, Q4 2019 earnings at ($0.25) EPS, FY2019 earnings at ($1.19) EPS, FY2020 earnings at ($1.06) EPS, FY2021 earnings at ($1.13) EPS, FY2022 earnings at ($0.86) EPS and FY2023 earnings at ($0.24) EPS.

Several other equities analysts also recently weighed in on DRNA. Leerink Swann initiated coverage on shares of Dicerna Pharmaceuticals in a report on Tuesday, November 27th. They set an “outperform” rating and a $24.00 price target on the stock. BidaskClub downgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, December 25th. Zacks Investment Research raised shares of Dicerna Pharmaceuticals from a “hold” rating to a “buy” rating and set a $13.00 price target on the stock in a report on Tuesday, January 8th. Chardan Capital raised shares of Dicerna Pharmaceuticals from a “neutral” rating to a “buy” rating and set a $18.00 price target on the stock in a report on Tuesday, January 22nd. Finally, ValuEngine downgraded shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Monday, February 25th. One investment analyst has rated the stock with a sell rating, two have given a hold rating and nine have assigned a buy rating to the company’s stock. The stock has an average rating of “Buy” and an average price target of $21.78.

Shares of NASDAQ:DRNA opened at $12.31 on Friday. Dicerna Pharmaceuticals has a 1-year low of $8.71 and a 1-year high of $17.98. The company has a market cap of $720.16 million, a price-to-earnings ratio of -10.26 and a beta of 2.40.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last issued its quarterly earnings results on Monday, March 11th. The biopharmaceutical company reported ($0.29) earnings per share for the quarter, missing the consensus estimate of ($0.23) by ($0.06). Dicerna Pharmaceuticals had a negative net margin of 1,438.68% and a negative return on equity of 65.91%. The firm had revenue of $1.54 million for the quarter, compared to analysts’ expectations of $8.38 million.

Several hedge funds have recently added to or reduced their stakes in DRNA. Zurcher Kantonalbank Zurich Cantonalbank lifted its holdings in shares of Dicerna Pharmaceuticals by 512.2% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,459 shares of the biopharmaceutical company’s stock worth $37,000 after buying an additional 2,894 shares in the last quarter. Legal & General Group Plc lifted its holdings in shares of Dicerna Pharmaceuticals by 38.7% in the fourth quarter. Legal & General Group Plc now owns 9,186 shares of the biopharmaceutical company’s stock worth $98,000 after buying an additional 2,561 shares in the last quarter. Bank of America Corp DE lifted its holdings in shares of Dicerna Pharmaceuticals by 30.3% in the fourth quarter. Bank of America Corp DE now owns 10,596 shares of the biopharmaceutical company’s stock worth $113,000 after buying an additional 2,465 shares in the last quarter. TD Asset Management Inc. purchased a new position in shares of Dicerna Pharmaceuticals in the fourth quarter worth $169,000. Finally, State Board of Administration of Florida Retirement System lifted its holdings in shares of Dicerna Pharmaceuticals by 19.9% in the fourth quarter. State Board of Administration of Florida Retirement System now owns 18,234 shares of the biopharmaceutical company’s stock worth $195,000 after buying an additional 3,024 shares in the last quarter. 92.81% of the stock is currently owned by hedge funds and other institutional investors.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery and development of ribonucleic acid interference (RNAi)-based pharmaceuticals. The company develops pharmaceuticals using its GalXC RNAi platform for the treatment of diseases involving the liver, including rare diseases, viral infectious diseases, chronic liver diseases, and cardiovascular diseases.

Featured Article: What are the most popular ETFs

Earnings History and Estimates for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.